Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race
Biohaven has acquired a priority review voucher from GW Pharma to accelerate the US review of rimegepant, its oral CGRP receptor antagonist for migraine. The firm is competing with Allergan and Lilly in a race to get the next oral treatment approved.
You may also be interested in...
Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.
Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.